N02CC04 • rizatriptan • Nervous system | Antimigraine preparations | Selective serotonin (5HT1) agonists
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used in the acute treatment of migraine, with or without aura. It works by constricting dilated blood vessels in the brain and inhibiting the release of neuropeptides that contribute to the neurogenic inflammation associated with migraine.
Rizatriptan is administered orally, usually in the form of tablets or orally disintegrating tablets, and is indicated for the rapid relief of headache pain and associated migraine symptoms such as nausea, photophobia, and phonophobia. Its effect typically begins within 30 minutes of administration.
Common side effects include dizziness, drowsiness, fatigue, and a sensation of pressure or tightness in the chest. In rare cases, severe adverse reactions such as myocardial ischemia or allergic reactions may occur. Rizatriptan is not indicated for migraine prevention and should be used with caution in patients with cardiovascular risk factors.
Rizatriptan is an effective therapeutic option for managing migraine attacks, providing rapid and significant symptom relief.
Substance: rizatriptan
Date of last drug list: 01-07-2013
Commercial code: W58253005
Concentration: 5mg
Pharmaceutical form: orodispersable tablets
Quantity: 18
Product type: generic
Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.